Track market-moving stories before they get noisy

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $226.13 and traded as high as $310.53. Charles River Laboratories International shares last traded at $302.7710, with a volume of 941,309 shares.

Analyst Ratings Changes Several analysts have weighed in on CRL shares. Argus set a $330.00 price objective on shares of Charles River Laboratories International in a research note on Thursday, September 17th. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Evercore set a $330.00 target price on shares of Charles River Laboratories International in a research report on Friday, September 25th. Royal Bank Of Canada raised their target price on shares of Charles River Laboratories International from $282.00 to $322.00 and gave the stock an “outperform” rating in a report on Friday, September 25th. Finally, CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target for the company. in a research report on Monday, July 20th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $302.33.

Read Our Latest Stock Report on CRL

Charles River Laboratories International Trading Up 1.3% The business has a 50-day moving average price of $288.02 and a two-hundred day moving average price of $226.13. The stock has a market capitalization of $14.45 billion, a P/E ratio of -62.43, a P/E/G ratio of 2.79 and a beta of 1.40. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. During the same period in the prior year, the firm posted $3.12 EPS. Charles River Laboratories International’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Insider Buying and Selling at Charles River Laboratories International In other Charles River Laboratories International news, EVP Shannon Parisotto sold 981 shares of the stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $308.44, for a total transaction of $302,579.64. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at $1,482,671.08. This represents a 16.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy C. Andrews sold 573 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total transaction of $163,442.52. Following the sale, the director owned 1,438 shares in the company, valued at $410,175.12. The trade was a 28.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 91,971 shares of company stock valued at $26,033,968 over the last three months. 1.30% of the stock is owned by insiders.

Institutional Trading of Charles River Laboratories International A number of institutional investors and hedge funds have recently made changes to their positions in the company. Mather Group LLC. boosted its stake in Charles River Laboratories International by 657.7% in the third quarter. Mather Group LLC. now owns 591 shares of the medical research company’s stock valued at $174,000 after buying an additional 513 shares in the last quarter. Triumph Capital Management grew its position in Charles River Laboratories International by 14,285.7% in the third quarter. Triumph Capital Management now owns 1,007 shares of the medical research company’s stock valued at $297,000 after acquiring an additional 1,000 shares during the last quarter. Mitchell & Pahl Private Wealth LLC raised its stake in Charles River Laboratories International by 2.0% during the third quarter. Mitchell & Pahl Private Wealth LLC now owns 5,635 shares of the medical research company’s stock worth $1,662,000 after acquiring an additional 112 shares in the last quarter. QRG Capital Management Inc. raised its stake in Charles River Laboratories International by 13.2% during the second quarter. QRG Capital Management Inc. now owns 2,183 shares of the medical research company’s stock worth $495,000 after acquiring an additional 255 shares in the last quarter. Finally, Tidal Investments LLC raised its stake in Charles River Laboratories International by 26.5% during the second quarter. Tidal Investments LLC now owns 6,371 shares of the medical research company’s stock worth $1,445,000 after acquiring an additional 1,334 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile (Get Free Report)

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.

Further Reading Five stocks we like better than Charles River Laboratories International Tesla Wants to Make Its Own Chips—What Could Go Wrong? IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver? PBF Energy’s Stunning Rally Faces a Critical Test Citi Stock Falls Despite Earnings Beat: What Investors Need to Know Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call.

WILMINGTON, Mass. & LONDON--(BUSINESS WIRE)---- $CRL #DrugDiscover--Charles River Laboratories International, Inc. (NYSE: CRL) and Autolomous today announced the launch of Apollo Orchestrate™, a new capability within Charles River's Apollo® platform that connects and digitizes laboratory execution, built on Autolomous's autoloMATE® digital Laboratory Execution System (LES). The launch demonstrates continued progress on Charles River's strategic commitment to modernize and digitize laboratory workflows. Apollo® Orches.

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?Charles River Laboratories International NYSE: CRL outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin and low-double-digit non-GAAP earnings-per-share growth.

Get CRL alerts:

Chief Executive Officer Birgit Girshick said the company’s refreshed strategic framework, called “Pathway to Purpose,” centers on three priorities: modernizing the company and industry, strengthening its scientific portfolio and growing through a customized client-centric approach.

“I want to simplify the company, invest where we can win, and translate this into revenue growth, margin expansion, and long-term shareholder value creation,” Girshick said.

Modernization program targets $300 million in savings Charles River said its “Create the Future” modernization initiative is expected to produce at least $300 million in cumulative incremental savings between 2027 and 2030, in addition to $300 million in cost savings implemented in recent years, primarily through restructuring.

Mark Mintz, the company’s chief information officer and head of global shared services, said the program will focus on AI, automation, digitization, workflow simplification and enterprise optimization. The company has identified more than 15 core business processes for simplification and has more than 50 AI-enabled projects supporting the transformation, according to Mintz.

“This is not simply a one-time cost program,” Mintz said. “It is a structural transformation designed to improve how work gets done and support sustainable growth and margin expansion over time.”

The company plans to use digital tools to support functions including scientific reporting, study design, commercial processes, financial processes, laboratory operations and manufacturing workflows. It also highlighted Apollo, its digital client engagement platform, which supports research-model purchases, vivarium management, study visibility and biologics-testing sample tracking. Mintz said Apollo has more than 18,000 client users and that about 92% of eligible users utilize the platform.

Investment focus includes bioanalysis and scientific technologies Girshick identified bioanalysis, or BioA, as one of Charles River’s clearest growth opportunities. The company currently performs BioA work primarily in the preclinical setting but is expanding capabilities to support clinical sample testing, rather than clinical trials. Management said that expansion could shift the company’s revenue mix from approximately 60% pre-IND and 40% post-IND toward a roughly even split.

The company expects BioA revenue to rise organically from approximately $300 million in 2025 to $450 million in 2030, according to Shannon Parisotto, corporate executive vice president of global Discovery and Safety Assessment, or DSA. Charles River is pursuing five organic BioA expansions and may consider acquisitions involving high-science, complex-modality providers, management said.

Charles River also said it is evaluating potential expansion of preclinical services in China, where management estimated the addressable market at $1.2 billion to $1.5 billion. Girshick said the company would take a measured approach and weigh potential investments against geopolitical risks, competition and alternative uses of capital.

Another scientific focus is new approach methodologies, or NAMs, which combine in vivo, in vitro and in silico methods. Chief Scientific and Innovation Officer Namandjé Bumpus said Charles River has more than 220 in vitro and in silico assays and methods operating across major organ systems.

Bumpus said the company does not view NAMs as an immediate replacement for animal-based research. Instead, Charles River is developing integrated test batteries designed to provide more detailed and decision-useful evidence alongside in vivo studies. The company also uses machine learning and historical study data in virtual control groups, which can reduce the number of live control animals used while maintaining scientific rigor.

“We need these in vivo models,” Bumpus said during the question-and-answer session, adding that she did not expect animal testing to be fully replaced during her lifetime.

Segment targets through 2030 Discovery and Safety Assessment: Charles River expects 5% to 7% organic revenue growth from 2027 through 2030 and non-GAAP operating margins of at least 27% by 2030. The company said its DSA business holds approximately 33% of the outsourced in vivo safety-assessment market. Manufacturing Solutions: The company targets 7% to 9% organic revenue growth and non-GAAP operating margins exceeding 40% by 2030. Management said the segment will benefit from recurring consumables revenue, microbial testing launches, biologics testing and the earlier divestiture of its CDMO business. Research Models & Services: Charles River projects 2% to 4% organic revenue growth and operating margins in the mid-20% range. Management expects growth in China, CRADL vivarium services and government and academic markets, while assuming mid-single-digit volume declines in North American research models. Chief Financial Officer Glenn Coleman said Charles River expects an improvement in market conditions, citing a net book-to-bill ratio above one for three consecutive quarters and a 1.19 ratio in the second quarter, its highest in nearly four years. He said proposal volumes have increased sequentially for three quarters and rose by a double-digit percentage year over year in the most recent quarter.

The company reaffirmed its 2026 guidance for revenue, operating margin and non-GAAP EPS, while stating that it expects to finish at the upper end of its revenue and non-GAAP EPS ranges. Coleman said organic sales declined 0.7% in the first half, but the company expects low-single-digit growth, or potentially slightly higher, in the second half.

Charles River ended June with approximately $2.6 billion of total debt and a net debt-to-EBITDA leverage ratio of about 2.5 times. Coleman said the company intends to maintain a long-term leverage range of two to three times, while retaining flexibility for strategic acquisitions.

Girshick said the company’s financial objectives are based on current initiatives rather than major unproven assumptions. “We know where the value is, we know what we need to do, and we are already executing on it,” she said.

About Charles River Laboratories International (NYSE:CRL)Charles River Laboratories International, Inc is a global provider of drug discovery, nonclinical development and laboratory services for pharmaceutical, biotechnology and medical device companies, as well as academic and government research institutions. The company supports customers throughout the development process, from early-stage research and target identification through preclinical testing and regulatory preparation.

Its offerings include research models and related products, discovery and development services, toxicology and safety assessment, efficacy testing, bioanalysis, and laboratory testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Charles River Laboratories International Right Now?Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

24.9.2026 20:05, DJI, SPX, QQQ

Americké akciové trhy se pohybují v mírně záporném pásmu, přičemž index Dow Jones odepisuje 0,38 % na 51 317,46 bodu, S&P 500 klesá o 0,12 % na 7 696,91 bodu a technologický Nasdaq Composite ztrácí 0,22 % na 26 876,34 bodu. Akcie postupně odmazávají hlubší ztráty díky zprávám o možném jednání mezi USA a Íránem o znovuotvření Hormuzského průlivu, což mírní obavy z vysokých cen energií a navazující inflace. Trhy však udržují pod tlakem prohlášení některých představitelů FEDu, kteří upozorňují na potřebu dalšího zvyšování úrokových sazeb.

Mezi sektory se nejvíce daří komunikačním službám se ziskem 1,4 %, energiím s růstem o 1 % a zdravotní péči, která přidává 0,6 %. Naopak nejslabším odvětvím jsou základní materiály se ztrátou 1,1 %, následované sektory průmyslu a informačních technologií, které shodně odepisují 0,6 %.

Na čele růstových akcií se nachází společnost Everpure (P) se ziskem 14 %. Výrazně posilují také Charles River Laboratories International (CRL) o 6,2 %, GoDaddy (GDDY) o 5,0 %, Illumina (ILMN) o 4,6 % a Royal Caribbean Cruises (RCL) o 4,4 %. Naopačnému tlaku čelí společnost MGM Resorts International (MGM), jejíž akcie propadají o 11 % v reakci na zprávu, že ze záměru na její převzetí odstoupila společnost People Inc. Ztráty zaznamenávají také Gen Digital (GEN) o 9,1 %, First Solar (FSLR) o 8,1 %, Rollins (ROL) o 6,9 % a Xylem (XYL) o 5,1 %.

Na komoditních trzích rostou ceny ropy. Americká ropa WTI přidává 3 % na 94,94 dolaru za barel a severomořský Brent se obchoduje kolem 106 dolarů. Spotové zlato naopak oslabuje o 0,6 % na 4 260,70 dolaru za unci. Na devizovém trhu posiluje dolarový index o 0,3 %, zatímco euro zůstává bez výraznějších změn na úrovni 1,1372 USD. Britská libra oslabuje o 0,1 % na 1,3220 USD a japonský jen ztrácí 0,4 % na 158,89 JPY za dolar. Výnosy dluhopisů pokračují v růstu. Desetileté americké dluhopisy dosahují výnosu 5,15 % a třicetileté dluhopisy vystupují na 5,44 %, což představuje nejvyšší úroveň od roku 2004.

Index Dow Jones -0,38 % na 51317,46 b.
S&P 500 -0,12 % na 7696,91 b.
Nasdaq Composite -0,22 % na 26876,34 b.

Index S&P 500 -0,12 % na 7696,91 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Komunikační služby +1,4 % Základní materiály -1,1 % Energie +1 % Průmysl -0,6 % Zdravotní péče +0,6 % Informační technologie -0,6 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Everpure (P) +14 % MGM Resorts International (MGM) -11 % Charles River Laboratories International (CRL) +6,2 % Gen Digital (GEN) -9,1 % GoDaddy (GDDY) +5,0 % First Solar (FSLR) -8,1 % Illumina (ILMN) +4,6 % Rollins (ROL) -6,9 % Royal Caribbean Cruises (RCL) +4,4 % Xylem (XYL) -5,1 %
Daniel Marván, Fio banka, a.s.

-

– Outlines Pathway to Purpose Strategy to Modernize the Company, Strengthen Its Scientific Portfolio, and Enhance the Client Experience –

– Issues Long-Term Financial Targets through 2030 –

– Reaffirms 2026 Financial Guidance with Revenue and Non-GAAP Earnings per Share Expected at the Upper Ends of Prior Ranges –

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.

Birgit Girshick, Chief Executive Officer, along with members of the senior management team, will highlight a refreshed strategic vision, Pathway to Purpose, to modernize the Company, strengthen its scientific portfolio, and drive profitable growth to enhance long-term shareholder value creation.

Ms. Girshick said, “Our Pathway to Purpose strategy is designed to strengthen Charles River’s position as a leading scientific partner to the biopharmaceutical industry. As innovation across drug development accelerates, we believe there are significant opportunities to leverage our scientific expertise, operational excellence, and client-centric approach to drive scalable, profitable growth and to lead the future of drug development.”

Pathway to Purpose is centered on three strategic initiatives:

Modernizing the Company to Drive Greater Productivity and Efficiency: Through its recently introduced Create the Future™ program, Charles River expects to generate over $300 million in cumulative savings from 2027 through 2030 by simplifying processes and increasing automation and digital enablement. The Company will expand its use of AI-assisted digital tools to improve operating efficiency, reduce drug development timelines, and enhance client satisfaction. Strengthening a World-Class Scientific Portfolio: Charles River will expand its innovative scientific capabilities through organic and inorganic investments. Priority investment areas include bioanalysis, in vitro testing, and related scientific solutions. Charles River expects its bioanalysis revenue to grow organically at a high-single-digit CAGR to approximately $450 million in 2030. Delivering a Customized, Client-Centric Approach: The Company’s client-centric approach will further enable it to capitalize on improving biopharmaceutical R&D demand, growth in biologics and complex modalities, the potential benefit of AI-assisted drug discovery, and the increasing complexity of scientific research. Charles River is expanding its Apollo™ cloud-based platform to create a more seamless client experience. Apollo™ now serves more than 18,000 client users through its scientific decision-support and e-commerce capabilities and was recently expanded to support Manufacturing Solutions’ clients. Through these initiatives and disciplined capital deployment, the Company intends to reinforce its leadership position in early-stage drug development with comprehensive regulated testing capabilities across the R&D continuum.

Financial Targets

In conjunction with Investor Day, the Company is reaffirming its 2026 financial guidance, which was last updated on August 5, 2026. The Company now expects revenue and non-GAAP earnings per share to be at the upper ends of their respective guidance ranges, primarily reflecting continued favorable demand from biopharmaceutical clients.

The Company is also introducing the following long-term financial targets through 2030:

2026
GUIDANCE(1)

2030
TARGET(2)

Revenue growth, organic (3)

Upper end of
0% – 1% growth

5% – 7%
2027-2030 CAGR

Non-GAAP operating margin (4)

21.0% – 21.3%

~24%

Non-GAAP EPS estimate (4)

Upper end of
$11.15 – $11.45

Low-double-digit
2027-2030 CAGR

  Footnotes:

(1) The reconciliations of GAAP to non-GAAP financial information for 2026 guidance, which were last updated on August 5, 2026, can be found on the Investor Relations section of the Company’s website at ir.criver.com.

(2) Financial targets through 2030 do not include the impact of future acquisitions or divestitures. The financial targets are not projections and do not constitute financial guidance; they are subject to significant uncertainties and contingencies and are based upon management’s current assumptions, which are subject to change.

(3) Organic growth (non-GAAP) is defined as reported revenue growth adjusted for completed acquisitions, divestitures, and foreign currency translation.

(4) Non-GAAP operating margin and earnings per share primarily excludes: (i) acquisition-related amortization; (ii) costs related to the evaluation and integration of acquisitions and divestitures; (iii) costs related to the Create the Future™ transformation program including site consolidation, severance, impairment, third-party consulting and professional services; and other costs related to restructuring actions and efficiency initiatives; and (iv) certain venture capital and other strategic investment losses/(gains), net, as well as certain other costs.

Investor Day Webcast Details

A link to the live webcast and presentation materials for Charles River’s 2026 Investor Day will be available at ir.criver.com shortly before the event begins. A replay of the webcast will be available on the same website following the conclusion of the event.

Use of Non-GAAP Financial Measures

This press release contains forward-looking, non-GAAP financial measures: organic revenue growth, non-GAAP operating margin, and non-GAAP earnings per share. We do not reconcile forward-looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of foreign currency translation, acquisitions, divestitures, and any other potential adjustments which would be reflected in any forecasted GAAP measure.

There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges and is consistent with how management measures and forecasts the Company’s performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations.

Caution Concerning Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding: the Company’s plans or prospects, expectations and long-term goals associated with our business; the Company’s expectations concerning future financial and operating performance, including the Company’s commitment to, and ability to create long-term value for shareholders and to successfully execute on the strategies described herein.

Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to, the ability to execute on, the results, and the impact of the Company’s Pathway to Purpose strategy and related initiatives. Furthermore, these and other risks relating to the Company are set forth in the documents filed by Charles River with the Securities and Exchange Commission, including without limitation, the Risk Factors in the Company’s Annual Report on Form 10-K filed February 18, 2026, as well as the Company’s other filings with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

More News From Charles River Laboratories International, Inc.

Back to Newsroom

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehensiv.

Charles River Laboratories International, Inc. (CRL) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDT

Company Participants

Birgit Girshick - CEO & Director
Glenn Coleman - Corporate Executive VP & CFO

Conference Call Participants

Kallum Titchmarsh - Morgan Stanley, Research Division

Presentation

Kallum Titchmarsh
Morgan Stanley, Research Division

Perfect. Good morning, everyone. Welcome to day 1 of Morgan Stanley's Global Healthcare Conference. I'm Kallum Titchmarsh, the life sciences analyst here at Morgan Stanley. Here today with the wonderful team from Charles River, we have Birgit Girshick, CEO; and then Glenn Coleman, CFO. And just before we get started, important disclosures, please see Morgan Stanley research disclosures website at www.morganstanley.com/researchdisclosures.

So thank you both for being here. Great to have you both.

Birgit Girshick
CEO & Director

Thank you. Thanks for having us.

Question-and-Answer Session

Kallum Titchmarsh
Morgan Stanley, Research Division

Birgit, you took over the role of CEO from Jim in May, 4 months now into this new role. How has that transition been so far? You're obviously at Charles River for quite some time beforehand across different responsibilities there. So maybe what surprised you leading the ship?

Birgit Girshick
CEO & Director

Yes. So the transition has been very smooth. As you said, I spent nearly my entire career at Charles River, and I know Charles River really well. So I know our strengths, but I also know where we need to be faster and sharper and had a great transition with Jim. So I was really able to prepare myself, give it a lot of thought. But what I did in addition was really looking to see that I get more feedback from our stakeholders.

So I spent the last 4 months literally visiting over 40 of our sites in 7 countries. I met with a

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:

Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, at 10:00 a.m. ET; andBaird 2026 Global Healthcare Conference on Tuesday, September 15th, at 9:40 a.m. ET.Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.

A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for at least two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260911072567/en/

Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity. Reaching full operational capacity in Q3 2026, the automated suite is a major investment in advanced.

Key Takeaways Charles River is sharpening its portfolio while expanding capacity in areas of strong client demand.Charles River's DSA bookings rose 12.6% sequentially, with backlog reaching $1.97 billion in Q2 2026.CRL expects a low-to-mid-single-digit 2026 RMS decline as North American research-model volumes weaken. Charles River Laboratories International, Inc. (CRL - Free Report) is well-poised to grow in the coming quarters owing to its strong research-model position, improving demand trends and flexible vivarium solutions. The company is streamlining its portfolio while expanding capacity in areas of strong demand. The Discovery and Safety Assessment (“DSA”) segment is also showing improving demand, bookings and backlog, supporting its growth prospects. Yet mixed demand trends and NHP-related cost volatility remain key risks. 

Over the past year, this Zacks Rank #2 (Buy) stock has surged 79% compared with the industry’s 11.2% rise and the S&P 500 composite’s 22.2% growth.

The renowned, non-clinical global drug development company has a market capitalization of $13.92 billion. Charles River has an earnings yield of 3.9%. The company surpassed earnings estimates in each of the trailing four quarters, delivering an average surprise of 5.9%.

Let’s delve deeper.

Upsides for CRL StockStrategic Deals Drive Growth: Charles River has completed the divestitures of its Contract Development and Manufacturing Organization and Cell Solutions businesses and certain European Discovery Services sites, sharpening the portfolio around regulated testing and manufacturing quality-control capabilities. At the same time, the company is investing in areas where client demand remains strong. It has five lab-science expansions under way globally, including new bioanalytical capacity at Heriot-Watt University’s Research Park in Scotland. Management noted that lab-science demand has increased over the past five years, supported by large-molecule bioanalysis, biomarkers and added testing requirements across regulated, nonregulated and clinical-development programs.

Image Source: Zacks Investment Research

RMS’ Prospects Seem Bright: Charles River continues to hold a leading position in research models, supported by a broad product and service offering. In the second quarter of 2026, RMS organic revenues declined 1.4%, an improvement from the 5.5% decrease in the first quarter as NHP shipment timing normalized. Lower small-model demand in North America and softer research model services were partly offset by continued demand from mid-tier biotech and Clinical Research Organization clients in China. The Charles River Accelerator and Development Lab model continues to offer clients flexible vivarium capacity without requiring internal infrastructure, preserving a capital-efficient value proposition as clients manage research spending.

DSA, A Potential Growth Driver: Charles River remains a leading provider of outsourced discovery, non-clinical development and regulated safety testing services. In the second quarter of 2026, DSA organic revenues increased 0.2%, its first organic growth since the third quarter of 2023. Net bookings rose 12.6% sequentially to $701 million, backlog increased to $1.97 billion, and net book-to-bill reached 1.19X, marking the third consecutive quarter above 1X and the highest level in nearly four years. The improvement was broad-based across global biopharma and small and midsized biotech clients.

The Cambodia and Mauritius NHP supply assets also support availability for complex biologics work, while lower Cambodian sourcing costs are expected to begin benefiting DSA margins in the third quarter and contribute more in the fourth quarter.

What Ails Charles River?Uneven Demand Recovery: Charles River’s demand environment is recovering, but the pace remains uneven across client groups and end markets. In the second quarter of 2026, small and midsized biotech revenues were essentially flat organically, while global biopharma revenues increased organically. Management continues to expect a low-to-mid-single-digit organic revenue decline in RMS for 2026 because North American research-model volumes are lower, and academic and government customers face flat NIH budgets and slower grant processing. DSA trends are better, but the recovery is gradual and uneven.

NHP Supply and Cost Variability: Charles River’s safety assessment and large-model activities remain exposed to variability in NHP sourcing, study mix and study-start costs. In the second quarter of 2026, DSA adjusted operating margin fell 180 basis points year over year to 25.6%, primarily because of higher study-related direct costs, even as NHP shipment timing normalized in RMS. The Cambodia acquisition may not fully eliminate sensitivity to NHP availability, utilization and study timing. The acquired supplier also adds integration requirements. Because NHP-related work carries attractive economics, changes in model costs or study mix can still create quarter-to-quarter variability in margins and earnings.

CRL Stock Estimate TrendThe Zacks Consensus Estimate for CRL’s 2026 earnings has increased 2.3% to $11.30 in the past 30 days.

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $3.90 billion, suggesting a 2.9% decrease from the year-ago reported number.

Other Key Picks

Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Teleflex (TFX - Free Report) .

Veracyte has an earnings yield of 4.5% against the industry’s negative 1.3% yield. Shares of the company have risen 43.4% compared to the industry’s 3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%. 

VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6% compared to the industry’s negative 1.3% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 35.8% against the industry’s 3% decline over the past year.

Teleflex, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.9% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have rallied 11.9% against the industry’s 3% decline over the past year.

Great Lakes Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,026 shares of the medical research company’s stock, valued at approximately $459,000.

A number of other hedge funds have also recently modified their holdings of CRL. Vanguard Group Inc. raised its holdings in Charles River Laboratories International by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after purchasing an additional 47,432 shares during the period. Invesco Ltd. lifted its position in Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock valued at $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. State Street Corp grew its holdings in Charles River Laboratories International by 2.2% during the fourth quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock valued at $373,364,000 after purchasing an additional 40,535 shares during the period. Dimensional Fund Advisors LP grew its holdings in Charles River Laboratories International by 14.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after purchasing an additional 210,260 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Charles River Laboratories International by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after acquiring an additional 9,756 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Here are the key news stories impacting Charles River Laboratories International this week:

Positive Sentiment: Charles River is collaborating with Medigen Vaccine Biologics to advance vaccine-development programs using next-generation sequencing. The partnership could expand CRL’s support for biologics and vaccine customers, although financial terms were not disclosed. Charles River Labs and Medigen Vaccine collaboration Positive Sentiment: Analysts highlight DSA’s return to organic growth, stronger bookings, and new testing capabilities as key drivers behind CRL’s approximately 88.6% one-year advance. These trends support the company’s strategy of broadening its role in drug-development services. Charles River rally drivers Neutral Sentiment: Options-market activity suggests traders are positioning for a potentially significant move in CRL shares, but the activity does not establish whether the anticipated move will be upward or downward. CRL options activity Negative Sentiment: Zacks cautions that the recent 33.3% monthly surge has raised the bar for execution. Margin pressure and a premium valuation may constrain upside unless bookings and guidance continue to improve. CRL valuation and rally outlook Negative Sentiment: Director Nancy Andrews sold 573 shares for approximately $163,443, reducing her direct holdings by 28.5%. The transaction is modest but adds to investor focus on insider selling after the stock’s rally. Nancy Andrews insider sale Negative Sentiment: EVP Shannon M. Parisotto sold 2,039 shares for approximately $599,711, reducing direct ownership by 29.8%; the sale was made under a pre-arranged Rule 10b5-1 trading plan, which lessens its signaling value. Shannon Parisotto insider sale Insider Activity In related news, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the transaction, the chief executive officer owned 36,013 shares in the company, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria L. Creamer sold 4,179 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total value of $1,083,029.64. Following the sale, the executive vice president directly owned 30,051 shares in the company, valued at $7,788,017.16. The trade was a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 132,429 shares of company stock worth $32,538,088. 1.30% of the stock is owned by insiders. Analyst Upgrades and Downgrades Several research analysts recently weighed in on the stock. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a report on Monday, August 10th. Mizuho set a $264.00 price target on shares of Charles River Laboratories International in a report on Monday, August 10th. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Morgan Stanley increased their price objective on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International has an average rating of “Moderate Buy” and a consensus price target of $255.65.

View Our Latest Analysis on Charles River Laboratories International

Charles River Laboratories International Trading Up 0.0% Shares of CRL opened at $295.23 on Monday. The company’s fifty day moving average is $234.99 and its 200 day moving average is $193.73. Charles River Laboratories International, Inc. has a fifty-two week low of $144.26 and a fifty-two week high of $299.32. The stock has a market capitalization of $14.09 billion, a PE ratio of -60.87, a P/E/G ratio of 3.06 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. During the same quarter last year, the business earned $3.12 earnings per share. Charles River Laboratories International’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.

Charles River Laboratories International Profile (Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Read More Five stocks we like better than Charles River Laboratories International VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? 3 Closed-End Funds to Maximize Dividend Payments Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy? $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

Key Takeaways CRL's Q2 earnings beat estimates, while 2026 earnings guidance rose to $11.15-$11.45 per share. DSA organic revenue growth returned, with bookings up 12.6% sequentially and backlog reaching $1.97 billion. RMS demand remains weak, while premium valuation raises the pressure for margins and bookings to improve. Charles River Laboratories International, Inc. (CRL - Free Report) shares have risen 33.3% over the past four weeks. The move has lifted expectations just as operating trends are beginning to improve.

Image Source: Zacks Investment Research

Second-quarter earnings, better Discovery and Safety Assessment demand indicators and higher 2026 guidance support the recovery case. Still, weak Research Models and Services demand, margin pressure and a premium valuation leave less room for execution missteps.

CRL's One-Month Surge Sets a Higher BarCharles River reported second-quarter 2026 company-defined non-GAAP earnings of $3.02 per share, down 3.2% year over year but 17.6% above the Zacks Consensus Estimate. Revenues of $1 billion declined 2.7% but topped the consensus mark by 3%.

Management also raised non-GAAP earnings guidance to $11.15-$11.45 per share from $10.80-$11.30. That combination gives investors more fundamental support for the rally, but the higher share price raises the bar for subsequent results.

Charles River's DSA Demand Signals Are ImprovingDiscovery and Safety Assessment organic revenues rose 0.2% in the second quarter, marking the segment's first organic growth since the third quarter of 2023. Net bookings increased 12.6% sequentially to $701 million while backlog reached $1.97 billion.

Net book-to-bill, a measure of bookings relative to revenues, improved to 1.19x, the third consecutive quarter above 1x. Medpace Holdings, Inc. (MEDP - Free Report) is among CRL's Medical Services peers, providing another reference point for outsourced research demand. IQVIA Holdings Inc. (IQV - Free Report) is another listed peer that can help investors gauge broader industry conditions.

CRL Margin Upside Depends on Study Costs and NHPsThe demand improvement has not yet translated into stronger DSA profitability. The segment's non-GAAP operating margin declined 180 basis points year over year to 25.6%, primarily because of higher study-related direct costs.

Charles River expects lower Cambodian non-human primate sourcing costs to begin benefiting DSA margins in the third quarter, with a larger contribution in the fourth quarter. The timing makes margin execution an important confirmation point for the recovery.

Charles River Still Faces RMS Demand WeaknessResearch Models and Services organic revenues fell 1.4% in the second quarter. That was better than the 5.5% decline in the first quarter as non-human primate shipment timing normalized.

North American small-model demand and research model services remained weak, partly offset by growth in China. Management still expects a low-to-mid-single-digit organic revenue decline for RMS in 2026, leaving the segment as a drag on a broader recovery.

CRL's Premium Valuation Raises Execution PressureCRL trades at 24.06X forward 12-month earnings, compared with 16.41X for its Zacks sub-industry and 22.14X for the Zacks Medical sector. Its five-year median is 18.44X.

Image Source: Zacks Investment Research

The premium means stronger bookings alone may not be enough to extend the rally. Investors will likely look for bookings to convert into revenues while expected sourcing savings and portfolio changes support margins.

CRL's Positive Signal Meets Weak Style ScoresThe near-term setup remains constructive but mixed. CRL currently carries a Zacks Rank #2 (Buy), and the Zacks Consensus Estimate for the current fiscal year's earnings has moved 2.69% higher over the past four weeks.

The stock has a VGM Score of F, with a Value Score of D, Growth Score of D and Momentum Score of F. Because Style Scores complement the Zacks Rank, those weak readings temper the favorable short-term estimate signal. Further gains remain possible, but sustaining the rally will require operating improvement to keep pace with a valuation that already reflects higher expectations.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Posted by Defense World Staff on Aug 11th, 2026

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) CAO Michael Gunnar Knell sold 6,645 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the sale, the chief accounting officer directly owned 11,852 shares in the company, valued at $3,086,023.76. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Charles River Laboratories International Stock Performance Shares of CRL stock opened at $276.34 on Tuesday. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $277.07. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The company has a 50 day moving average price of $216.74 and a 200 day moving average price of $189.45. The firm has a market capitalization of $13.19 billion, a price-to-earnings ratio of -56.98, a price-to-earnings-growth ratio of 2.77 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. Charles River Laboratories International’s revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 EPS for the current year.

Hedge Funds Weigh In On Charles River Laboratories International Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its stake in Charles River Laboratories International by 0.8% during the 4th quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after buying an additional 47,432 shares during the period. Assetmark Inc. boosted its position in Charles River Laboratories International by 17.9% in the 4th quarter. Assetmark Inc. now owns 43,809 shares of the medical research company’s stock valued at $8,739,000 after buying an additional 6,666 shares during the last quarter. Eos Management L.P. acquired a new stake in shares of Charles River Laboratories International during the fourth quarter valued at about $839,000. M&T Bank Corp increased its position in shares of Charles River Laboratories International by 1,424.9% during the fourth quarter. M&T Bank Corp now owns 27,997 shares of the medical research company’s stock worth $5,585,000 after acquiring an additional 26,161 shares during the last quarter. Finally, WINTON GROUP Ltd purchased a new stake in shares of Charles River Laboratories International during the fourth quarter worth about $9,209,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades A number of research analysts recently weighed in on CRL shares. CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 target price on the stock. in a report on Monday, July 20th. Piper Sandler set a $300.00 price target on Charles River Laboratories International in a research note on Monday. Evercore restated an “outperform” rating on shares of Charles River Laboratories International in a report on Wednesday, August 5th. BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Twelve investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $255.65.

Check Out Our Latest Research Report on CRL

About Charles River Laboratories International (Get Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

See Also Five stocks we like better than Charles River Laboratories International SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat 3 Dividend Champion Utilities for a Market That Can’t Sit Still These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI First Solar’s Profit Engine Faces a New Policy Test in Washington Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBay Colony Advisory Group Inc d b a Bay Colony Advisors Grows Position in Vanguard Mid-Cap ETF $VO

Have you looked into how Charles River Laboratories (CRL - Free Report) performed internationally during the quarter ending June 2026? Considering the widespread global presence of this medical research equipment and services provider, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.

The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become essential for investors to comprehend how much a company relies on these foreign markets, as this understanding reveals the firm's potential for consistent earnings, its capacity to harness different economic cycles, and its overall growth prospects.

Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

While analyzing CRL's performance for the last quarter, we found some intriguing trends in revenues from its overseas segments that Wall Street analysts commonly model and monitor.

The company's total revenue for the quarter stood at $1 billion, declining 2.7% year over year. Now, let's delve into CRL's international revenue breakdown to gain insights into the significance of its operations beyond home turf.

Unveiling Trends in CRL's International RevenuesOf the total revenue, $13.12 million came from Other International, including Brazil and Israel during the last fiscal quarter, accounting for 1.3%. This represented a surprise of +102.75% as analysts had expected the region to contribute $6.47 million to the total revenue. In comparison, the region contributed $9.4 million, or 0.9%, and $10.33 million, or 1%, to total revenue in the previous and year-ago quarters, respectively.

Canada accounted for 12.7% of the company's total revenue during the quarter, translating to $127.51 million. Revenues from this region represented a surprise of +8.19%, with Wall Street analysts collectively expecting $117.86 million. When compared to the preceding quarter and the same quarter in the previous year, Canada contributed $109.57 million (11%) and $135.59 million (13.1%) to the total revenue, respectively.

During the quarter, Europe contributed $263.07 million in revenue, making up 26.2% of the total revenue. When compared to the consensus estimate of $257.15 million, this meant a surprise of +2.3%. Looking back, Europe contributed $277.58 million, or 27.9%, in the previous quarter, and $281.86 million, or 27.3%, in the same quarter of the previous year.

Asia Pacific generated $60.52 million in revenues for the company in the last quarter, constituting 6% of the total. This represented a surprise of +18.13% compared to the $51.23 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia Pacific accounted for $55.48 million (5.6%), and in the year-ago quarter, it contributed $54.5 million (5.3%) to the total revenue.

Anticipated Revenues in Overseas MarketsWall Street analysts expect Charles River to report a total revenue of $953.04 million in the current fiscal quarter, which suggests a decline of 5.2% from the prior-year quarter. Revenue shares from Other International, including Brazil and Israel, Canada, Europe and Asia Pacific are predicted to be 1.1%, 12.1%, 26.2%, and 4.4%, corresponding to amounts of $10.72 million, $114.84 million, $249.42 million, and $42.21 million, respectively.

For the full year, the company is projected to achieve a total revenue of $3.85 billion, which signifies a fall of 4.1% from the last year. The share of this revenue from various regions is expected to be: Other International, including Brazil and Israel at 1% ($40.1 million), Canada at 11.9% ($459.08 million), Europe at 27% ($1.04 billion), and Asia Pacific at 5.3% ($202.41 million).

Closing RemarksCharles River's leaning on foreign markets for its revenue stream presents a mix of chances and challenges. Therefore, a vigilant watch on its international revenue movements can greatly aid in projecting the company's future direction.

In an era of growing international interdependencies and escalating geopolitical disputes, Wall Street analysts are vigilant in tracking these trends for businesses with a global reach, in order to refine their predictions of earnings. It should be noted, however, that a multitude of other elements, such as a company's domestic position, also play a significant role in shaping the earnings forecasts.

At Zacks, we place significant importance on a company's evolving earnings outlook. This is based on empirical evidence demonstrating its strong influence on a stock's short-term price movements. Invariably, there exists a positive relationship -- an upward revision in earnings estimates is typically mirrored by a rise in the stock price.

Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.

Charles River, bearing a Zacks Rank #2 (Buy), is expected to outperform the broader market's movements in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Charles River Laboratories' Recent Stock Market PerformanceOver the preceding four weeks, the stock's value has appreciated by 14.6%, against an upturn of 3.4% in the Zacks S&P 500 composite. In parallel, the Zacks Medical sector, which counts Charles River among its entities, has depreciated by 0.4%. Over the past three months, the company's shares have seen an increase of 77.3% versus the S&P 500's 6% increase. The sector overall has witnessed an increase of 10.8% over the same period.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Second-Quarter 2026 Financial Results.

Charles River Laboratories (CRL - Free Report) came out with quarterly earnings of $3.02 per share, beating the Zacks Consensus Estimate of $2.72 per share. This compares to earnings of $3.12 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +11.03%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $1.96 per share when it actually produced earnings of $2.06, delivering a surprise of +5.1%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Charles River, which belongs to the Zacks Medical Services industry, posted revenues of $1 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 3.43%. This compares to year-ago revenues of $1.03 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Charles River shares have added about 17.4% since the beginning of the year versus the S&P 500's gain of 13%.

What's Next for Charles River?While Charles River has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Charles River was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $3.05 on $943.09 million in revenues for the coming quarter and $11.05 on $3.85 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Services is currently in the top 38% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Nutex Health Inc. (NUTX - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.

This company is expected to post quarterly earnings of $5.26 per share in its upcoming report, which represents a year-over-year change of +278.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Nutex Health Inc.'s revenues are expected to be $215.2 million, down 11.8% from the year-ago quarter.

Charles River Laboratories has rebounded 40% from last year, driven by improved organic revenue and a positive inflection in order trends. CRL raised guidance, now expecting slightly positive organic growth and EPS of $11.15–$11.45, with margin expansion locked in through divestitures and cost cuts. Segment performance is mixed: DSA shows strong backlog and book-to-bill, while RMS faces U.S. weakness offset by China strength; manufacturing margins benefit from divestitures.

Key Takeaways CRL beat second-quarter earnings and revenue estimates, while shares rose 7.9% pre-market. CRL's DSA organic revenues rose 0.2% on higher regulated safety study volume; Manufacturing gained 1.3%. CRL lifted 2026 non-GAAP EPS guidance to $11.15-$11.45 and narrowed its revenue decline outlook. Charles River Laboratories International, Inc. (CRL - Free Report) reported second-quarter 2026 company-defined non-GAAP earnings of $3.02 per share, down 3.2% year over year. The reported earnings topped the Zacks Consensus Estimate by 17.6%.

GAAP net loss was 3 cents per share compared to GAAP earnings of $1.06 per share in the year-ago period.

Revenues of $1.00 billion declined 2.7% (up 0.1% organically) year over year but beat the Zacks Consensus Estimate by 3%. 

Following the announcement, CRL shares rose 7.9% in the pre-market trading today.

Charles River's DSA Business Shows Demand GainsDSA revenues totaled $606.5 million, down 1.9% year over year on a reported basis. Organic revenues increased 0.2%, driven mainly by higher study volume for regulated safety assessment services.

The segment's GAAP operating margin rose 60 basis points to 20.5%, aided by lower intangible-asset amortization and reduced third-party legal costs tied to a non-human primate supply matter. The non-GAAP margin fell 180 basis points to 25.6% because of higher study-related direct costs.

CRL's RMS Sales Decline on North America WeaknessRMS revenues totaled $209.5 million, down 1.8% from the year-ago quarter’s level. Organic revenues declined 1.4% primarily due to lower sales of small research models in North America and weaker research model services, partly offset by growth in China.

The segment's GAAP operating margin improved 50 basis points to 17.3%, mainly because of lower amortization following the Cell Solutions divestiture. The non-GAAP margin contracted 80 basis points to 24.5% on lower volume and an unfavorable geographic revenue mix.

Charles River's Manufacturing Margins ExpandManufacturing revenues amounted to $188.1 million, down 6.3% year over year, mainly because of the CDMO divestiture. Organic revenues rose 1.3%, supported by higher revenues in the Microbial Solutions business.

GAAP operating margin surged to 34.9% from 6.0% a year earlier. The non-GAAP margin expanded 500 basis points to 37.8%, with the CDMO business and the benefit from its divestiture driving the improvement.

CRL's Margin PerformanceThe gross profit in the reported quarter was $363.4 million, up 1.8% from the prior-year quarter’s level. The gross margin of 36.2% expanded approximately 159 basis points (bps) year over year.

Selling, general & administrative expenses increased 19.5% year over year to $228.9 million. Operating profit totaled $119.9 million, up 19.7% from the prior-year quarter’s level. The operating margin expanded approximately 224 bps to 11.9%.

CRL's Cash Flow and Buyback ActivityCash and cash equivalents amounted to $192.0 million as of June 27, 2026, compared with $191.8 million at the end of the first quarter. Cumulative net cash provided by operating activities at the end of the quarter was $220.8 million compared with $376.3 million a year ago.

CRL repurchased 0.6 million shares for $100 million during the second quarter at an average price of $174 per share. Year-to-date repurchases totaled $300 million, leaving $700 million available under the company's authorization.

Charles River Raises Its 2026 OutlookCharles River now expects reported revenues to decline 3.5% to 2.5% in 2026, compared with its prior projection for a 5.5% to 4.0% decrease. The Zacks Consensus Estimate for 2026 revenues implies a decline of 4.2% year over year. 

The company raised its non-GAAP earnings guidance to $11.15-$11.45 per share from $10.80-$11.30.  The Zacks Consensus Estimate for the metric is pegged at $11.05 per share.

Our Take on CRLCharles River exited the second quarter of 2026 with earnings and revenues beating estimates. Reported revenue decline reflected the effects of completed divestitures. Organic growth increased due to gains in DSA and Manufacturing offset weakness in RMS. However, the expansion of both margins in the quarter looks encouraging.

On a positive note, Charles River raised its 2026 financial outlook driven by improving demand trends in the DSA segment and better-than-expected performance in the Manufacturing segment.

CRL’s Zacks Rank and Other Key PicksCharles River currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Quest Diagnostics (DGX - Free Report) and Medpace (MEDP - Free Report) .

Intuitive Surgical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.

Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, exceeding the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.

DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.

Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.

MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%.

Posted by Defense World Staff on Aug 4th, 2026

California State Teachers Retirement System lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 21.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,972 shares of the medical research company’s stock after acquiring an additional 10,207 shares during the period. California State Teachers Retirement System owned 0.12% of Charles River Laboratories International worth $9,828,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in CRL. Los Angeles Capital Management LLC purchased a new stake in Charles River Laboratories International during the fourth quarter worth approximately $42,000. Sfam LLC purchased a new position in shares of Charles River Laboratories International in the 4th quarter valued at $43,000. Activest Wealth Management raised its stake in shares of Charles River Laboratories International by 10,900.0% in the 4th quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of Charles River Laboratories International by 98.0% during the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 145 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new position in shares of Charles River Laboratories International during the 4th quarter valued at $46,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets CRL has been the subject of several recent research reports. Mizuho increased their price target on Charles River Laboratories International from $192.00 to $230.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a research report on Friday, May 8th. Morgan Stanley increased their target price on Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Finally, BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a report on Wednesday, July 1st. Eleven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $220.75.

Get Our Latest Analysis on Charles River Laboratories International

Insider Buying and Selling at Charles River Laboratories International In related news, Director James C. Foster sold 75,000 shares of the business’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares of the company’s stock, valued at $7,109,100. This represents a 70.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Trading Down 0.8% NYSE:CRL opened at $230.58 on Tuesday. The company has a market cap of $11.11 billion, a PE ratio of -61.33, a P/E/G ratio of 2.59 and a beta of 1.38. The business’s 50 day moving average is $207.99 and its two-hundred day moving average is $188.00. The company has a quick ratio of 1.03, a current ratio of 1.36 and a debt-to-equity ratio of 0.90. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $242.73.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

About Charles River Laboratories International (Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Featured Articles Five stocks we like better than Charles River Laboratories International SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control Why Rare Earth Processing Could Be the Real 2027 Opportunity The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks? Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAirgain (AIRG) Projected to Announce Quarterly Earnings on Wednesday

NEXT HEADLINE »Popular, Inc. $BPOP Shares Bought by California State Teachers Retirement System

Key Takeaways Charles River will report Q2 results on Aug. 5, with revenues and EPS expected to decline from last year.CRL expects pressure in RMS, DSA and Manufacturing Solutions amid softer demand and divestitures.CRL has a positive Earnings ESP. It beat estimates in each of the last four reported quarters. Charles River Laboratories International, Inc. (CRL - Free Report) is scheduled to report second-quarter 2026 results on Aug. 5, before market open.

In the last reported quarter, the company’s adjusted earnings per share (EPS) of $2.06 surpassed the Zacks Consensus Estimate by 5.1%. Charles River beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 9.31%.

Q2 Estimates for CRLThe Zacks Consensus Estimate for the company’s second-quarter revenues is pegged at $970.8 million, suggesting a 5.9% decline from the year-ago reported figure.

The Zacks Consensus Estimate for EPS projects a decrease of 12.8% year over year to $2.72. The estimate has dropped 1.1% in the past 30 days.

Let’s briefly review the company’s performance leading up to the announcement.

Trends Likely to Shape CRL’s Q2 ResultsResearch Models and Services (“RMS”)In the second quarter of 2026, the segment likely faced pressure from lower sales of small models and research model services. The first-quarter headwind from the timing of NHP shipments, affecting large model revenues, is expected to have eased, consistent with management’s expectations. Meanwhile, lower volumes in North America may have continued to weigh on small model revenues, as in-house research activity among large pharma and midsized biotech clients is yet to fully recover. 

In addition, subdued demand from early-stage biotech clients likely kept occupancy levels at Charles River Accelerator and Development Lab (CRADL) constrained, weighing on RMS revenue growth.

On the positive side, demand for small models in China from mid-tier biotech and CRO clients likely remained solid. During the quarter, Charles River launched an enhanced In Vitro Fertility (IVF) service bundle to accelerate rat-model programs across therapeutic areas, including oncology, neurology, cardiology, and metabolic. The offering provides researchers with a new avenue to advance drug development research and help bring treatments to patients faster.

Our model estimates that Charles River’s RMS business revenues will decrease 5.5% in the second quarter of 2026.

Discovery and Safety Assessment (“DSA”)For the past several quarters, Charles River has been navigating a challenging demand environment within this segment. Discovery Services revenues are likely to have declined in the second quarter, partly as a result of site consolidation activities.

Earlier this year, the company signed a definitive agreement to divest certain European assets within this business to IQVIA Holdings Inc. for roughly $145 million in cash, subject to customary closing adjustments.  The transaction was expected to close during the second quarter of 2026.

Meanwhile, Safety Assessment services likely continued to generate stable revenues. The acquisition of K.F. Cambodia’s assets earlier this year, now Charles River Cambodia, is expected to have strengthened and secured the company’s NHP supply chain for its Safety Assessment operations.

Management also indicated that the overall DSA demand environment was tracking in line with its expectations, as reflected in a net book-to-bill of 1.04x and a slight sequential increase in backlog at the end of the first quarter. Net bookings remained above the $600 million threshold, supported by continued strength from the small and mid-sized biotech client base.

Demand trends for global biopharmaceutical clients remained moderately below year-over-year levels, while healthy proposal activity in the first quarter signaled continued improvement in bookings momentum. All these trends are expected to have influenced the second-quarter performance as well.

Per our model estimate, Charles River’s DSA business revenues are expected to decline 5.5% year over year.

Manufacturing SolutionsWithin this, the Microbial Solutions business likely delivered another solid performance, aided by the Endosafe and Celsis manufacturing quality control testing platforms. Underlying demand for both Microbial Solutions and Biologics Testing may have remained healthy, with clients continuing to advance their late-stage development and commercial programs.

Further, the segment’s profitability is also expected to have benefited from higher revenues and benefits from ongoing cost-saving efforts.

A key development occurred in May 2026, when the company completed the sale of its contract development and manufacturing products and services (“CDMO”) and Cell Solutions businesses to GI Partners (GI) for future contingent performance-based payments up to $50.0 million, subject to certain customary closing adjustments. The completed divestiture is expected to have reduced Manufacturing Solutions revenues in the second quarter.

Our model estimates segment revenues to decrease 8.2% year over year.

Earnings Whispers for CRL StockPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is the case here:

Earnings ESP: Charles River has an Earnings ESP of +1.43%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: Charles River currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks Rank #1 stocks here.

Other Key MedTech PicksHere are some medical stocks worth considering, as these also have the right combination of elements to post an earnings beat this time:

CVS Health (CVS - Free Report) has an Earnings ESP of +1.42% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 5.

CVS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.79%. The Zacks Consensus Estimate for the company’s second-quarter EPS indicates an increase of 3.3% from the year-ago quarter’s figure.

Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2. The company is slated to release fourth-quarter fiscal 2026 results on Aug. 11.

CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.27%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for a rise of 16.4% from the year-ago quarter’s figure.

Cencora, Inc. (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank #2. The company is slated to release third-quarter fiscal 2026 results on Aug. 5.

COR’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 1.59%. The Zacks Consensus Estimate for the company’s third-quarter EPS implies an increase of 9.3% from the year-ago quarter’s figure.

28.7.2026 16:15, KO, UPS, BA, PYPL

Index Dow Jones +0,86 % na 52659,78 b., S&P 500 -0,28 % na 7392,46 b., Nasdaq Composite -1,33 % na 24600,91 b.

Americké akcie zahájily úterní seanci smíšeně. Index Dow Jones posiluje, zatímco širší index S&P 500 mírně oslabuje a technologický Nasdaq Composite klesá výrazněji pod tlakem polovodičových titulů. Akcie výrobce paměťových čipů Micron odepisují přibližně 12 %, zatímco akcie společností Sandisk a Western Digital klesají o 17 %, respektive 15 %. Negativní sentiment navazuje na pondělní výprodej technologických titulů a prohloubil jej také 11% propad jihokorejského indexu KOSPI.

Investoři také vyhodnocují další várku kvartálních výsledků.

Jedním z reportujících je americká logistická společnost UPS. Ta zveřejnila výsledky hospodaření za druhé čtvrtletí roku 2026. Tržby i očištěný zisk na akcii překonaly odhady analytiků a společnost zvýšila celoroční výhled tržeb. UPS zároveň oznámila, že úspěšně dokončila postupné omezování objemů od Amazonu. Akcie UPS -5,6 %.

Dále také reportovala své výsledky za druhé čtvrtletí roku 2026 americká platební společnost PayPal. Očištěný zisk na akcii překonal průměrný odhad analytiků, stejně jako výnosy a objem zpracovaných plateb. Očištěný provozní zisk i marže však meziročně klesly. Akcie PayPal +4,5 %.

Americká nápojářská společnost Coca-Cola rovněž reportovala výsledky hospodaření za druhý kvartál roku 2026. Porovnatelný zisk na akcii i očištěné organické tržby překonaly očekávání analytiků. Společnost zaznamenala také silnější než očekávaný růst objemu prodejů a zvýšila celoroční výhled organických tržeb i porovnatelného zisku na akcii. Akcie Coca-Cola +6,8 %.

Také americký výrobce letadel Boeing reportoval výsledky hospodaření za druhý kvartál roku 2026. Tržby i provozní hotovostní tok překonaly očekávání analytiků. Výnosy segmentů Komerční letadla a Obrana, vesmír a bezpečnost rostly meziročně a překonaly konsensus. Jádrová ztráta na akcii byla naopak vyšší, než analytici očekávali. Akcie Boeing +3,8 %.

Index S&P 500 -0,28 % na 7392,46 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Nezbytná spotřeba +3,9 % Informační technologie -2,7 % Zdravotní péče +2,9 % Průmysl -0,5 % Základní materiály +2,4 % Zbytná spotřeba +0,4 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna IQVIA Holdings (IQV) +14 % Corning (GLW) -19 % Sherwin-Williams (SHW) +8,6 % Sandisk Corp (SNDK) -17 % Charles River Laboratories International (CRL) +7,8 % Dell Technologies (DELL) -15 % Gartner (IT) +7,4 % Coherent Corp (COHR) -15 % Solventum Corp (SOLV) +7,2 % Lumentum Holdings (LITE) -14 %
Zdroj: Bloomberg

Marek Krejčiřík
Fio banka, a.s.
Prohlášení

On July 23, 2026, Charles River Laboratories International Inc (CRL) shares rose 4.8% to a current price of $229.29. This movement marks a significant increase

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Charles River Laboratories (CRL - Free Report) , a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Charles River Laboratories currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?Let's discuss some of the components of the Momentum Style Score for CRL that show why this medical research equipment and services provider shows promise as a solid momentum pick.

Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.

For CRL, shares are up 1.18% over the past week while the Zacks Medical Services industry is down 0.95% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 23.87% compares favorably with the industry's 3.26% performance as well.

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Over the past quarter, shares of Charles River Laboratories have risen 36.62%, and are up 46.24% in the last year. On the other hand, the S&P 500 has only moved 7.33% and 21.58%, respectively.

Investors should also pay attention to CRL's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. CRL is currently averaging 832,892 shares for the last 20 days.

Earnings OutlookThe Zacks Momentum Style Score also takes into account trends in estimate revisions, in addition to price changes. Please note that estimate revision trends remain at the core of Zacks Rank as well. A nice path here can help show promise, and we have recently been seeing that with CRL.

Over the past two months, 2 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost CRL's consensus estimate, increasing from $11.02 to $11.05 in the past 60 days. Looking at the next fiscal year, 4 estimates have moved upwards while there have been no downward revisions in the same time period.

Bottom LineGiven these factors, it shouldn't be surprising that CRL is a #2 (Buy) stock and boasts a Momentum Score of B. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Charles River Laboratories on your short list.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company, to provide Good Manufacturing Practice (GMP) Next Generation Sequencing (NGS) services for cell characterization. The collaboration helps Arovella achieve its goal of creating a unique Invariant Natural Killer T (iNKT) cell therapy platform for cancer treatment. In a successful IND application, the FDA.